222 related articles for article (PubMed ID: 30918508)
1. Early Enzyme Replacement Therapy Improves Hearing and Immune Defects in Adenosine Deaminase Deficient-Mice.
Xu X; Negandhi J; Min W; Tsui M; Post M; Harrison RV; Grunebaum E
Front Immunol; 2019; 10():416. PubMed ID: 30918508
[No Abstract] [Full Text] [Related]
2. Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy.
Moretti FA; Giardino G; Attenborough TCH; Gkazi AS; Margetts BK; la Marca G; Fairbanks L; Crompton T; Gaspar HB
Sci Rep; 2021 Dec; 11(1):23221. PubMed ID: 34853379
[TBL] [Abstract][Full Text] [Related]
3. Comparison of elapegademase and pegademase in ADA-deficient patients and mice.
Murguia-Favela L; Min W; Loves R; Leon-Ponte M; Grunebaum E
Clin Exp Immunol; 2020 May; 200(2):176-184. PubMed ID: 31989577
[TBL] [Abstract][Full Text] [Related]
4. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
[TBL] [Abstract][Full Text] [Related]
5. Effects of enzyme replacement therapy on immune function in ADA deficiency patient.
Nakazawa Y; Kawai T; Uchiyama T; Goto F; Watanabe N; Maekawa T; Ishiguro A; Okuyama T; Otsu M; Yamada M; Hershfield MS; Ariga T; Onodera M
Clin Immunol; 2015 Dec; 161(2):391-3. PubMed ID: 26122173
[No Abstract] [Full Text] [Related]
6. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
[TBL] [Abstract][Full Text] [Related]
7. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency.
Grunebaum E; Cutz E; Roifman CM
J Allergy Clin Immunol; 2012 Jun; 129(6):1588-93. PubMed ID: 22409989
[TBL] [Abstract][Full Text] [Related]
9. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
[TBL] [Abstract][Full Text] [Related]
10. First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.
Migliavacca M; Assanelli A; Ponzoni M; Pajno R; Barzaghi F; Giglio F; Ferrua F; Frittoli M; Brigida I; Dionisio F; Nicoletti R; Casiraghi M; Roncarolo MG; Doglioni C; Peccatori J; Ciceri F; Cicalese MP; Aiuti A
Front Immunol; 2018; 9():113. PubMed ID: 29456531
[TBL] [Abstract][Full Text] [Related]
11. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling.
Apasov SG; Blackburn MR; Kellems RE; Smith PT; Sitkovsky MV
J Clin Invest; 2001 Jul; 108(1):131-41. PubMed ID: 11435465
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
[TBL] [Abstract][Full Text] [Related]
13. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.
Hicks ED; Hall G; Hershfield MS; Tarrant TK; Bali P; Sleasman JW; Buckley RH; Mousallem T
J Clin Immunol; 2024 Apr; 44(5):107. PubMed ID: 38676811
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
15. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
Tartibi HM; Hershfield MS; Bahna SL
Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies.
Grunebaum E; Cohen A; Roifman CM
Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):630-8. PubMed ID: 24113229
[TBL] [Abstract][Full Text] [Related]
17. Morbidity in an adenosine deaminase-deficient patient during 27 years of enzyme replacement therapy.
Grunebaum E; Reid B; Naqvi A; Hershfield MS; Kim VH; Muller MP; Hicks LK; Lee E; Betschel S; Roifman CM
Clin Immunol; 2020 Feb; 211():108321. PubMed ID: 31812707
[TBL] [Abstract][Full Text] [Related]
18. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
Kohn DB; Gaspar HB
J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
[TBL] [Abstract][Full Text] [Related]
19. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.
Kohn DB; Hershfield MS; Puck JM; Aiuti A; Blincoe A; Gaspar HB; Notarangelo LD; Grunebaum E
J Allergy Clin Immunol; 2019 Mar; 143(3):852-863. PubMed ID: 30194989
[TBL] [Abstract][Full Text] [Related]
20. Management of ADA-Deficient SCID Patient on Adagen During Pregnancy.
Shams M; Kobrynski L
J Clin Immunol; 2019 Nov; 39(8):846-848. PubMed ID: 31620946
[No Abstract] [Full Text] [Related]
[Next] [New Search]
